Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with significant revenue growth, increased cash flow, and substantial net income improvements. Positive factors include raised guidance, successful LUPKYNIS sales, and a substantial share repurchase plan. Despite some concerns in the Q&A about unclear management responses and terminated studies, overall sentiment remains positive due to strong financial metrics and optimistic future guidance.
Key Financial Performance
Total revenue (Q4 2025) $77.1 million, up 29% compared to $59.9 million in Q4 2024. The increase was driven by strong LUPKYNIS sales.
Net product sales of LUPKYNIS (Q4 2025) $74.2 million, up 29% compared to $57.6 million in Q4 2024. Growth attributed to continued momentum in product adoption.
Net income (Q4 2025) $210.8 million, up 14,957% from $1.4 million in Q4 2024. The significant increase was primarily due to a $175.1 million income tax benefit from the release of a valuation allowance on deferred tax assets.
Net income before income taxes (Q4 2025) $35.7 million, up 2,875% from $1.2 million in Q4 2024. Growth driven by strong revenue performance.
Diluted earnings per share (Q4 2025) $1.53, up 15,200% from $0.01 in Q4 2024. Increase reflects higher net income.
Cash flows from operating activities (Q4 2025) $45.7 million, up 52% from $30.1 million in Q4 2024. Growth due to improved operational performance.
Total revenue (Full Year 2025) $283.1 million, up 20% compared to $235.1 million in 2024. Excluding a $10 million milestone payment in 2024, revenue increased by 26%, driven by LUPKYNIS sales.
Net product sales of LUPKYNIS (Full Year 2025) $271.3 million, up 25% from $216.2 million in 2024. Growth attributed to strong product adoption.
Net income (Full Year 2025) $287.2 million, up 4,852% from $5.8 million in 2024. Increase driven by a $173 million income tax benefit from the release of a valuation allowance on deferred tax assets.
Net income before income taxes (Full Year 2025) $114.2 million, up 1,443% from $7.4 million in 2024. Growth driven by strong revenue performance.
Diluted earnings per share (Full Year 2025) $2.07, up 5,075% from $0.04 in 2024. Increase reflects higher net income.
Cash flows from operating activities (Full Year 2025) $135.7 million, up 206% from $44.4 million in 2024. Growth due to improved operational performance.
Cash, cash equivalents, restricted cash, and investments (End of 2025) $398 million, up from $358.5 million at the end of 2024. Increase reflects strong cash flow generation.
Share repurchase (Full Year 2025) 12.2 million common shares repurchased for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LUPKYNIS sales: Strong sales growth of 25% year-over-year in 2025, with net product sales reaching $271.3 million. Expected sales for 2026 are projected to grow by 12% to 16%, reaching $305 million to $315 million.
Aritinercept development: Initiated clinical study for one autoimmune disease and plans to start another study in the first half of 2026. The drug showed promising results in Phase I trials, with robust and long-lasting effects.
Revenue growth: Total revenue for 2025 was $283.1 million, up 20% from 2024. Excluding a one-time milestone payment in 2024, revenue increased by 26%.
Net income: Net income for 2025 was $287.2 million, a significant increase of 4,852% from $5.8 million in 2024, driven by a $173 million income tax benefit.
Cash flow: Cash flows from operating activities for 2025 were $135.7 million, up 206% from $44.4 million in 2024.
Share repurchase: Repurchased 12.2 million common shares for $98.2 million, reducing fully diluted shares outstanding from 149.8 million to 139.7 million.
2026 Guidance: Projected total revenue of $315 million to $325 million, representing an 11% to 15% increase compared to 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company expects a slower growth rate in 2026 (12%-16% increase in net product sales) compared to the 25% growth achieved in 2025, indicating potential market saturation or increased competition.
Regulatory Hurdles: The company relies on the successful clinical development and regulatory approval of aritinercept for future growth, which is inherently uncertain and subject to regulatory risks.
Strategic Execution Risks: The company is expanding into new clinical studies for aritinercept, which could strain resources and operational focus if not managed effectively.
Economic Uncertainties: The company’s financial performance is partially dependent on favorable tax benefits, such as the release of valuation allowances on deferred tax assets, which may not recur in the future.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Aritinercept Development: Aurinia has initiated a clinical study of aritinercept in one autoimmune disease and plans to initiate a clinical study in an additional autoimmune disease in the first half of 2026.
2026 Revenue Guidance: Aurinia expects total revenue of $315 million to $325 million, representing an 11% to 15% increase compared to 2025.
2026 Net Product Sales Guidance: Net product sales of LUPKYNIS are projected to be $305 million to $315 million, reflecting a 12% to 16% growth compared to 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: For the year ended December 31, 2025, the company repurchased 12.2 million common shares for $98.2 million and fully diluted shares outstanding were reduced from $149.8 million to $139.7 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the underlying assumptions for the 2026 guidance and observations from the first two months of the year?
A:The strategy for the commercial business of LUPKYNIS focuses on leveraging data from the AURORA trial and guidelines promoting early diagnosis and treatment of lupus nephritis. No specific steer for the first quarter was provided, but historical trends were emphasized as predictors.
Q:What is the status of the Phase III and open-label studies in the vocal study and pediatric study?
A:The vocal study was terminated due to recruitment challenges. Negotiations with the FDA are planned to meet pediatric commitments. The disease primarily affects women in mid-life, making the pediatric burden and business opportunity smaller.
Q:Can we expect a development update for aritinercept in early 2026, and what details can be shared about the study design?
A:An update is expected in the second quarter of 2026. Details on trial design and size are not disclosed yet, but the focus is on BAFF April inhibition for autoimmune diseases.
Q:What is driving the strong performance of LUPKYNIS, and are there specific metrics available?
A:Growth is driven by patient adherence, persistency, and consistent average price per commercial patient. Historical growth patterns are the best predictors for future performance. Specific commercial metrics are no longer provided.
Q:How much of the growth is coming from rheumatologists versus nephrologists, and what is the impact of ACR guidelines?
A:Growth slightly favors rheumatologists, with an increasing trend over the last two years. ACR guidelines emphasize early diagnosis and treatment, but there is room for improvement in adherence to these guidelines.
Q:What is the impact of Gazyva's approval on LUPKYNIS, and is it incorporated into the guidance?
A:No immediate impact from Gazyva's launch has been observed. The guidance incorporates factors like new competition. LUPKYNIS has a competitive profile due to its rapid reduction in proteinuria.
Q:Do you expect global markets to catch up to the U.S. in terms of LUPKYNIS penetration?
A:No, due to differences in pricing, reimbursement, and treatment guidelines. Global markets contribute to growth but are not expected to match U.S. penetration.
Q:Are physicians combining B-cell and T-cell therapies, or choosing one over the other?
A:There is potential for combining B-cell and T-cell therapies for more effective treatment. Research and development work may explore this further.
Q:What updates can be expected for aritinercept, and is there a preferred indication?
A:More updates are expected in the second quarter of 2026. There is no preferred indication, but the focus is on addressing multiple autoimmune diseases.
Q:What is Roche doing to grow the market for Gazyva, and how are physicians responding?
A:Roche's efforts appear focused on the larger SLE population rather than lupus nephritis specifically. Physicians are considering sequencing therapies, but no specific marketing strategies for Gazyva in lupus nephritis have been observed.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on trial design and size for aritinercept, as well as metrics for LUPKYNIS performance. They also gave a non-specific response regarding Roche's marketing strategies for Gazyva and updates on aritinercept.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Conference QA
Full Conference
Full Update
Instructions President
Japan milestone
LUPKYNIS approval
LUPKYNIS income
LUPKYNIS momentum
Officer today
Pharmaceuticals Full
QA session
Update today
activity cash
activity period
allowance tax
asset income
benefit release
flow activity
income tax
introduction result
investment share
period product
progress today
rate product
release valuation
remark Instructions
result LUPKYNIS
sale introduction
sale rate
session remark
share cash
tax asset
tax benefit
tax share
today Full
today Miller
valuation allowance
AUPH Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call shows strong financial performance with significant revenue growth, increased cash flow, and substantial net income improvements. Positive factors include raised guidance, successful LUPKYNIS sales, and a substantial share repurchase plan. Despite some concerns in the Q&A about unclear management responses and terminated studies, overall sentiment remains positive due to strong financial metrics and optimistic future guidance.
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals strong financial performance with significant revenue and EPS growth. The company raised its revenue guidance and demonstrated confidence in continued growth, especially with LUPKYNIS. Although there were some uncertainties regarding FDA requests, the overall sentiment remains positive due to the raised guidance and strong financial metrics. The Q&A section reinforced positive trends and growth potential, contributing to a positive stock price prediction.
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Positive7-31
The earnings call summary highlights strong financial performance, including significant revenue growth, improved margins, and a notable increase in net income. The company also announced a share repurchase program, which is generally viewed favorably by investors. Despite management's reluctance to provide specific guidance on certain R&D projects, the overall sentiment from the earnings call is positive, supported by raised guidance and improved financial health. The Q&A section did not reveal any major concerns that would significantly offset the positive financial results and strategic initiatives.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript
Positive5-13
The earnings call presents a strong financial performance with a 24% revenue increase and a transition to net income, alongside a robust gross margin. The share repurchase program indicates confidence in the stock. Despite potential challenges like supply chain issues and patent litigation, the optimistic guidance and strategic focus on growth drivers are positive. The Q&A highlights management's proactive approach to market dynamics, suggesting stability and potential growth. Given these factors, the stock is likely to see a positive movement, with a potential increase of 2% to 8% over the next two weeks.
AUPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
